# 1 Effect of Immunoadsorption on clinical presentation and

# 2 immune alterations in COVID-19–associated ME/CFS

Moritz Anft<sup>1\*</sup>, Lea Wiemers<sup>1\*</sup>, Kamil Rosiewicz<sup>2\*</sup>, Adrian Doevelaar<sup>1</sup>, Sarah
Skrzypczyk<sup>1</sup>, Julia Kurek<sup>1</sup>, Sviatlana Kaliszczyk<sup>1,2</sup>, Maximilian Seidel<sup>1</sup>, Ulrik
Stervbo<sup>1,2</sup>, Felix S. Seibert<sup>1</sup>, Timm H. Westhoff<sup>1</sup>, Nina Babel<sup>1,2</sup>

- 5 Stervbo, Telix 5. Seibert, Tillin TI. Westholi, Nina Dabe
- 6 \* These authors contributed equally to the manuscript

7 <sup>1</sup>Center for Translational Medicine and Immune Diagnostics Laboratory, Medical

8 Department I, Marien Hospital Herne, University Hospital of the Ruhr-University

- 9 Bochum, Hölkeskampring 40, 44625 Herne, Germany
- 10 <sup>2</sup>Berlin Institute of Health, Berlin-Brandenburg Center for Regenerative Therapies,
- 11 and Institute of Medical Immunology, Charité Universitätsmedizin Berlin, Corporate
- 12 Member of Freie Universität Berlin, Humboldt-Universität zu Berlin Augustenburger
- 13 Platz 1, 13353 Berlin, Germany
- 14

17

15 Corresponding author:

16 Prof. Nina Babel

Center for Translational Medicine, Medical Department I, Marien Hospital Herne,
University Hospital of the Ruhr-University Bochum, Hölkeskampring 40, 44625
Herne, Germany and Berlin Institute of Health, Charité – Universitätsmedizin Berlin,
Augustenburger Platz 1, 13353 Berlin, Germany

- 22
- 23 Email: <u>nina.babel@rub.de; nina.babel@charite.de</u>
- 24 Keywords: SARS-CoV-2, Post-Covid, Immunoadsorption

It is made available under a CC-BY-NC-ND 4.0 International license .

## 25 Abstract

26 Autoreactive antibodies (AAB) are currently being investigated as causative or 27 aggravating factors during post-COVID. In this study we analyze the effect of 28 immunoadsorption therapy on symptom improvement and the relationship with 29 immunological parameters in post-COVID patients exhibiting symptoms of Myalgic 30 Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). This observational study 31 includes 12 post-COVID patients exhibiting a predominance of ME/CFS symptoms 32 alongside increased concentrations of autonomic nervous system receptors (ANSR) 33 autoantibodies and neurological impairments. We found that following 34 immunoadsorption therapy, the ANSR autoantibodies were nearly eliminated from 35 the patients' blood. The removal of IgG antibodies was accompanied by a decrease 36 of pro-inflammatory cytokines including IL4, IL2, IL1β, TNF and IL17A serum levels, 37 and a significant reduction of soluble spike protein. Notably, a strong positive 38 correlation between pro-inflammatory cytokines and ASNR-AABs β1, β2, M3, and M4 39 was observed in spike protein-positive patients, whereas no such correlation was 40 evident in spike protein-negative patients. 30 days post-immunoadsorption therapy, 41 patients exhibited notable improvement in neuropsychological function and a 42 substantial amelioration of hand grip strength was observed. However, neither self-43 reported symptoms nor scores on ME/CSF questionnaires showed a significant 44 improvement and a rebound of the removed proteins occurring within a month.

It is made available under a CC-BY-NC-ND 4.0 International license .

## 46 Introduction

47 While the SARS-CoV-2 pandemic has decreased in intensity over time due to 48 vaccinations and the emergence of less pathogenic virus variants, some patients 49 manifest an array of different symptoms several months after the initial COVID-19 50 infection. These sequelae are collectively termed Long- or Post-COVID. The detailed 51 research into Post-COVID reveals it to be a heterogeneous clinical picture with over 52 200 documented different symptoms arising from various causes.<sup>1</sup> These symptoms 53 are often nonspecific and can impact multiple organs. Alongside cardiovascular 54 symptoms like palpitations or chest pain,<sup>2–4</sup> patients often report respiratory issues such as breathlessness.<sup>5</sup> Importantly, neurological and cognitive symptoms including 55 56 cognitive decline, memory impairment, and fatigue are prevalent among patients 57 experiencing severe Post-COVID effects, leading to significant limitations and even complete immobilization.<sup>6–8</sup> These symptoms associate with autoantibodies against 58 G protein-coupled receptors (GPCRs) of autonomic nervous system.<sup>9</sup> 59

Based on current research findings, four main causes can be broadly distinguished
 as responsible for the array of symptoms.<sup>10</sup>

1.) Persistent SARS-CoV-2 virus reservoirs in tissues: Numerous studies have identified SARS-CoV-2 RNA in various tissues,<sup>11,12</sup> as lung, lymph nodes, and plasma.<sup>13–15</sup> Additionally, in post-COVID patients, soluble spike protein has been detected in plasma even a year after initial SARS-CoV-2 infection.<sup>16</sup> It is hypothesized that active, persistent reservoirs of SARS-CoV-2 virus exist in the tissues of a significant portion of post-COVID patients, contributing to the development of subsequent post-COVID symptoms.<sup>17</sup>

69 2.) Autoantibody (AAB) formation:<sup>18</sup> Infection with SARS-CoV-2 can trigger the 70 formation of autoantibodies targeting components of the immune system, the 71 cardiovascular system, the thyroid gland, as well as rheumatoid-specific 72 autoantibodies and antibodies against G-protein-coupled receptors (GPCR).<sup>19</sup> 73 Studies show a correlation in the concentration of GPCR AAB with the severity of 74 neurological symptoms.<sup>20</sup>

It is made available under a CC-BY-NC-ND 4.0 International license .

75 3.) Reactivation of latent viruses: Particularly, the reactivation of various herpes
76 viruses like EBV and HHV-6 has been observed in post-COVID patients, correlating
77 with mitochondrial fragmentation and decreased energy metabolism.<sup>21</sup>

4.) Tissue damage from inflammatory processes: Post-COVID patients exhibit
elevated levels of pro-inflammatory cytokines such as IL-1ß, IL-6, TNF, or IP10,
which can lead to neurological and kidney damage or diabetes mellitus.<sup>22-24</sup>
Additionally, microvascular blood clots with endothelial dysfunction have been
detected in a substantial number of patients, associated with symptoms like fatigue,
thrombosis, and microclots.<sup>25,26</sup>

84 The presence of autoantibodies in the majority of post-COVID patients makes 85 immunoadsorption (IA) an attractive therapeutic strategy. There are a variety of 86 different adsorbents, allowing the non-selective removal of all subclasses of 87 immunoglobulins such as IgG or more selective removal of disease-specific 88 molecules such as lipoproteins and CRP. In the context of post-COVID syndrome, 89 IgG immunoadsorption is particularly relevant since it can specifically eliminate 90 autoantibodies. However, preliminary reports on the efficacy of IA in post-COVID are contradictory, rising the need to establish a broader scientific basis.<sup>27–29</sup> 91

This study aims to explore the impact of IA on neuropsychological impairments in relation to humoral and cellular immune response in post-COVID patients with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). The objective is to explore the impact of IA-therapy on diverse markers associated with post-COVID conditions, including autoantibodies directed against autonomic nervous system receptors, soluble spike protein levels, pro-inflammatory cytokines, and the composition of the cellular immune system, both pre- and thirty days after therapy.

It is made available under a CC-BY-NC-ND 4.0 International license .

### 99 **Results**

100 In this study, 12 post-COVID patients with ME/CSF symptoms and high levels of 101 GCPR AAB against autonomic nervous system receptors (ANSR) were evaluated for 102 clinical symptoms, physical and mental health status and immunological 103 characteristics before and after immunoadsorption (IA) therapy. The patients were 104 two-thirds female and with a median age of 50 and a median BMI of 25.25. Among 105 them, 4 out of 12 had ME/CSF developed after SARS-CoV-2 infection, while the 106 remaining 8 described their ME/CSF originally induced by other factors, later 107 aggravated by a subsequent SARS-CoV-2 infection. Table 1 demonstrates patient 108 characteristics and comorbidities. Inclusion criterium was elevated levels of at least 3 109 of the 4 ANSR proteins \beta1-adrenergic receptor (>15 U/mL), \beta2-adrenergic receptor 110 (>8 U/mL), M3-mACh receptor (>6 U/mL), and M4-mACh receptor (>10.7 U/mL). 111 Over a span of 10 days, patients underwent 5 sessions of IA-therapy, with 112 comprehensive screening conducted prior to the first session, after the last session 113 and 30 days after the last session. Health status and symptoms were assessed while 114 physical through detailed anamnesis, examinations encompassed 115 quantification of handgrip strength. Neurological and mental well-being were 116 quantified via the SF-36 questionnaire and various fatigue scores, while dysfunction 117 of the autonomic nervous system was gauged using the COMPASS-31 score. Blood 118 was immunologically analyzed during both assessments and following the last IA 119 session (Figure 1A).

# 120 IA-therapy leads to a strong decrease in ANSR-AABs and to an improvement in 121 multiple physical and neuropsychological factors

122 Quantifying the ANSR autoantibodies in the patients' serum immediately after the 123 final therapy session revealed that the levels of autoantibodies was significantly 124 reduced below their respective threshold values through IA. 30 days later, however, 125 the concentration of autoantibodies had returned to a slightly, but not significantly, 126 lower level compared to the time before therapy (Figure 1B). 30 days after IA-127 therapy, the patients had median autoantibody levels of 93.9% ( $\beta$ 1), 74.8% ( $\beta$ 2), 128 82.4% (M3), and 88.8% (M4) compared of the baseline levels before IA 129 (Supplemental Table S1). In addition, several physical and neuropsychological were 130 observed following the IA. Patients exhibited significantly increased hand strength

It is made available under a CC-BY-NC-ND 4.0 International license .

post-therapy (Figure 1C). Moreover, the overall score of the CERAD test battery was
significantly higher at the one-month follow-up measurement, primarily attributed to
enhancements in word learning, fluent speaking, and the Trail Making Test B (Figure
124 1D).

#### 135 IA-therapy does not lead to self-perceived changes

136 In addition to these objective measurements, several questionnaires and anamnesis 137 were used to assess patients' self-perception of whether and how their symptoms 138 and physical and mental health changed after the therapy (Table 2). The surveys 139 revealed no significant differences in the perception of physical and mental health 140 following the IA-therapy. Neither in the SF-36 questionnaire regarding health-related 141 quality of life nor in the Chandler Fatigue Score, Bell Score, or the Canadian criteria 142 for ME/CFS showed a significant improvement or deterioration due to the therapy 143 (Table 2 – upper section). Additionally, the self-reported symptoms of the patients did 144 not differ 30 days after the last IA compared to before the therapy (Table 2 - lower 145 section).

#### 146 **Temporary reduction in pro-inflammatory cytokines**

147 The concentration of pro-inflammatory cytokines in the serum of patients was 148 examined before and after the IA. Especially IL-4, IL-2, IL-1β, TNF and IL-17A were 149 significantly reduced immediately after the IA compared to the pre-therapy level. 150 Similar to the concentration ANSR AABs, the concentration of all these cytokines 151 rose back to a similar level as before the IA-therapy in the follow-up analysis 30 days 152 later. Interestingly, the concentration of TGF<sup>β1</sup> increased significantly directly after IA 153 and dropped back to the pre-IA level in the follow-up analysis, and the concentration 154 of IL-8 was significantly reduced after IA-therapy (Figure 2). The concentration of 155 other cytokines such as IP-10, MCP-1, IL-6 and IL-10 were not changed by the 156 therapy (Supplemental Figure S1). In addition, 5 of the 12 patients had an acute EBV 157 infection with an elevated EBV load during the whole study, and the viral load did not 158 change during and after IA-therapy (Supplementary Figure S2).

#### 159 Cellular immunity is unaffected by IA

160 To explore if the perturbations in pro-inflammatory cytokines during IA-therapy had 161 any effect on the composition of T cell populations, the major T cell populations

It is made available under a CC-BY-NC-ND 4.0 International license .

before and 30 days after IA-therapy were examined. While there were no differences
in the percentage of total CD4<sup>+</sup> and CD8<sup>+</sup> T cells, patients demonstrated significantly
more naive and significantly fewer memory CD4<sup>+</sup> T cells and additionally significantly
fewer CXCR5 expressing follicular helper cells in the follow-up examination
compared to the data before the start of IA-therapy (Figure 3A+3C).

T cells may become exhausted in a prolonged pro-inflammatory.<sup>30</sup> We therefore explored whether this is the case in post-COVID before and after IA-therapy. The frequency of PD-1 expression on CD4<sup>+</sup> and CD8<sup>+</sup> T-cells prior to the therapy was within previously observed ranges (Figure 3A+C)<sup>31</sup>. Except for a significant decrease in Tim-3 expressing CD4 T cells, there were no differences in the expression of exhaustion markers PD-1, Tim-3, CTLA-4, or Lag-3 directly or 30 days after IA (Figure 3 A+C and Supplemental Figure S3).

174 To investigate if the autoimmunity towards autonomic nervous system receptors 175 extended to the T cells, PBMC were stimulated with pooled lysates of  $\beta 1/\beta 2$ -176 adrenoceptors and muscarinic M3/M4 receptors, respectively (Figure 3B+D). 177 Simultaneously, the potential impact on cellular immunity to SARS-CoV-2 was 178 examined by additionally stimulating of PBMC with a pool of SARS-CoV-2 spike 179 protein overlapping peptides (Figure 3B+D). ANSR specific T cells were quantified by 180 assessing the expression of CD137 on CD8<sup>+</sup> T cells and CD137 and CD154 on CD4<sup>+</sup> 181 T cells. Following IA-therapy, there were no discernible differences in the 182 percentages of CD4 and CD8 T cells specific to  $\beta 1/\beta 2$ -adrenoceptors or muscarinic 183 M3/M4 receptors compared to the respective frequencies before IA-therapy. 184 Moreover, although a slight yet significant decrease was noted specifically in the 185 proportion of naive CD4 T cells targeting M3+M4 after IA, no significant differences 186 were observed in the proportions of naive, memory, and exhausted ANSR-specific T 187 cells post-IA (Figure 3B+D and supplemental Figure S4).

#### 188 IA-Therapy leads to a temporary reduction of SARS-CoV-2 spike protein

Several studies have shown that a subset of post-COVID patients have detectable levels of soluble spike protein in their blood.<sup>16,17</sup> The next step was to investigate the development of spike protein levels in the patients in this study before the IA-therapy, immediately after the last IA and at follow-up. Before the first IA, soluble spike protein was detected in 6 out of 12 patients, with a median concentration of 207.7 pg/mL.

It is made available under a CC-BY-NC-ND 4.0 International license .

Following the IA-therapy, the concentration of soluble spike protein significantly dropped to 22.8 pg/mL, but rebounded to a median of 207.5 pg/mL by the 30-day follow-up examination (Figure 4A). Except for one patient, the IA-therapy also significantly reduced the concentration of SARS-CoV-2 spike protein specific antibodies, but these levels also returned to their initial values within the 30 days following IA (Figure 4B). However, we found no differences in the frequency of spike protein specific CD4<sup>+</sup> or CD8<sup>+</sup> T cells after the IA-therapy (Figure 4C).

# 201 Correlation between neurological symptoms, virological and immunological 202 status

203 As stated above, the ratio of patients identified with soluble spike protein at study 204 start was 50:50, whereas 100% of patients showed detectable SARS-CoV-2 specific 205 antibodies. This interesting result led to the question, if there are possible differences 206 between these two groups based on the detected soluble spike protein (groups 207 named as "spike-" and "spike+"). First, spike+ patients were characterized by 208 significantly strong positive correlations between spike+ protein and SARS-CoV-2 209 specific antibodies, ANSR autoantibodies ( $\beta$ 1,  $\beta$ 2 and M3) and pro-inflammatory 210 cytokines IP-10 and IL-6 (Figure 4D). SARS-CoV-2 specific antibodies showed not 211 only nearly the same significant correlation with ANSR autoantibodies ( $\beta$ 2, M3 and 212 M4) but also with pro-inflammatory cytokines IL-2, IL-1β, IL-6 and IL-12p70 and a 213 significant negative correlation to the anti-inflammatory cytokine TGF<sup>β1</sup>. In general, 214 all ANSR autoantibodies showed very strong correlations to all cytokines except for 215 MCP-1, INFy and TGF $\beta$ 1. This result was in strong contrast to spike- patients. Here, 216 SARS-CoV-2 spike protein specific antibody levels correlated only positively with 217 blood levels of IL-1 $\beta$  and INFy. Interestingly, ANSR autoantibody levels ( $\beta$ 2, M3, M4) 218 showed a significant negative correlation to TGF<sup>β1</sup> blood levels. Only the positive 219 correlation between ANSR autoantibody levels and SARS-CoV-2 specific antibody 220 levels had spike- and spike+ patients in common (Figure 4D).

Next, the detected levels of soluble spike protein, SARS-CoV-2 specific antibodies and ANSR autoantibodies were correlated with the monitored clinical ME/CSF data. Again, spike+ patients showed a slightly different correlation profile than spikepatients. Soluble spike protein levels correlated significantly positive with MBSQ total score, while significantly negative with CERAD-Plus score and CERAD-Plus (word list learning) (Figure 4E).

It is made available under a CC-BY-NC-ND 4.0 International license .

227 This study shows that TheraSorb IA-therapy has the potential to improve the 228 neuropsychological state of ME/CFS, but has no positive impact on self-perceived 229 symptoms and mental health. In addition to ANSR-AABs, it effectively removes the 230 soluble spike protein, decreases pro-inflammatory cytokines and increase 231 inflammatory cytokine TGFβ. However, these improvements are highly transient, with 232 a resurgence of the eliminated proteins happening within a month. Further 233 therapeutic steps are needed to be implemented to provide a long-term 234 immunological and symptomatic improvements

It is made available under a CC-BY-NC-ND 4.0 International license .

## 235 **Discussion**

236 Although the SARS-CoV-2 pandemic is over, humankind is still struggling with its 237 consequences years later. The occurrence of post-COVID after SARS-CoV-2 238 infections poses major challenges for both patients and healthcare providers. The 239 multiple symptoms and underlying causes make diagnosis and treatment complex 240 and difficult. ANSR autoantibodies are associated with disease severity in ME/CSF 241 and their removal is associated with moderate improvement in symptoms in a previous study.<sup>28</sup> The present study shows that the health status of post-COVID 242 243 patients with ME/CFS symptoms and high ANSR autoantibody levels objectively 244 improved after IA-therapy. However, the affected patients did not perceive any 245 improvement as reflected in the self-reported symptoms.

246 In the present study, all patients had high titers of ANSR autoantibodies against 247  $\beta 1/\beta 2$ -adrenoceptor and muscarinic M3/M4 receptor. These ANSR and other GPCR 248 autoantibodies were earlier associated with the occurrence and worsening of multiple diseases like cardiovascular or rheumatic diseases,<sup>32-34</sup> and several studies have 249 shown a correlation between the presence of these ANSR autoantibodies and the 250 severity of post-COVID.<sup>9,35–37</sup> In the context of ME/CSF and post-COVID, it has been 251 252 shown that ANSR autoantibodies may be associated with Postural Orthostatic 253 Tachycardia Syndrome (POTS).<sup>38,39</sup> It is suggested that these ANSR autoantibodies 254 can disrupt autonomic nervous system function by interfering with signaling pathways 255 through binding to ANSRs, leading to symptoms such as excessive increase in heart rate upon standing, dizziness, and fatigue.<sup>40</sup> The patients in this study also reported 256 257 these neurological and hemodynamic symptoms and were diagnosed with fatigue. 258 Self-assessments using the SF-36 questionnaire revealed substantial deficits in both 259 physical and mental health. Additionally, the Bell and Chalder Fatigue Scores were 260 low, consistent with findings from studies on post-COVID patients with ME/CFS symptoms.<sup>41</sup> IA-therapy could effectively remove ANSR autoantibodies in patients 261 262 with ME/CSF and provided a moderate improvement in symptoms in the period shortly after therapy.<sup>28,42</sup> In line with this, an overall score increase in the CERAD+ 263 264 neuropsychological test as well as an increase in hand strength after removal of the 265 ANSR autoantibodies in this study was observed.

It is made available under a CC-BY-NC-ND 4.0 International license .

As also reported in other studies,<sup>28,42</sup> the levels of autoantibodies returned to their 266 267 original levels one month after therapy, which could be the reason that in contrast to 268 the improvement of objective symptoms, there was no demonstrated improvement in 269 the quantified fatigue scores and self-reported symptoms by the patients in the 270 follow-up. While neurological symptoms such as tiredness, cephalgia and brain fog 271 were present in almost all patients before therapy, they did not improve by IA-therapy 272 and the removal of ANSR autoantibodies. Accordingly, physical and mental health 273 were at the same low level after IA-therapy as before treatment, suggesting that 274 short-term removal of these AABs from the blood by IA-therapy cannot effectively 275 treat post-COVID symptoms. In contrast, removal of ANSR autoantibodies in a post-276 COVID patient using the DNA aptamer BC 007 resulted in a significant and four-week 277 lasting improvement in symptoms such as fatigue symptoms, taste and capillary microcirculation<sup>43</sup>. It is possible that a long-lasting DNA aptamer neutralizes ANSR 278 279 autoantibodies over an extended period, rather than only targeting the antibodies 280 present during the therapy, as is the case with IA-therapy. Moreover, IA-therapy can 281 only filter AABs out of the blood, whereas DNA aptamers can also act at the tissue level.44 282

283 Interestingly, changes in pro-inflammatory cytokine levels were detected after the IA-284 therapy. While some cytokines, such as IL-2, IL-4, and IL-17A, were reduced 285 immediately after the final IA-therapy TGF $\beta$ 1 levels were elevated. Other cytokines, 286 like IP-10 and MCP-1, were not significantly affected by the therapy. The reason for 287 the changes in cytokine levels after IA remains speculative. The different impact of IA 288 on certain cytokines demonstrates that this is not a pure mechanical cytokine 289 elimination. There might be a general reduction in inflammation after IA, as 290 autoantibodies drive inflammation via the activation of the complement system or direct antibody-dependent activation of immune cells.<sup>45–47</sup> Furthermore, patients with 291 292 infectious or autoimmune diseases have autoantibodies against some cytokines that 293 bind to the IA column, which could also remove bound cytokines.<sup>48–50</sup>

While the presence of ANSR autoantibodies indicate a defective immunotolerance after a viral infection,<sup>51,52</sup> the existence of soluble spike protein in post-COVID patients may indicate an active, persistent infection with SARS-CoV-2 viruses as it is currently discussed. Persistent viral reservoirs are known from other RNA viruses such as Ebola or Measles and are found in various tissues.<sup>53,54</sup> The presence of

It is made available under a CC-BY-NC-ND 4.0 International license .

299 soluble SARS-CoV-2 spike protein in 6 of the 12 patients suggests that half of the 300 post-COVID patients in this study contain active virus reservoirs in their tissues that 301 release spike protein into the bloodstream. Interestingly, spike protein was also 302 largely removed from the patients' blood with IA-therapy, even though they were not 303 expected to bind to the Ig-column. However, since high titers of SARS-CoV-2 spike 304 protein specific antibodies were detected in all patients, it is likely that these 305 antibodies bound to soluble spike protein, leading to their removal along with the 306 antibodies during IA-therapy. Notable, there was no improvement in self-reported 307 symptoms after IA-therapy associated with the removal of spike proteins in patients 308 with soluble spike protein, which is consistent with the observation that spike positive 309 patients do not show significant correlations between spike level and ME/CSF test 310 scores. Whether and how soluble spike protein itself has a direct pathogenic effect or 311 if the active virus reservoirs lead to the manifestation and exacerbation of post-312 COVID symptoms is not yet clear. It is discussed that soluble spike protein directly 313 leads to the formation of fibrin and amolytic microclots, which should be prevented by removing spike protein from the body.<sup>55</sup> Additionally, it has been shown in mice that 314 315 spike protein injected in the brain can lead to neuropsychological impairments that are similar to post-COVID symptoms,<sup>56</sup> although it remains highly unclear, whether 316 317 the spike protein crosses the blood-brain barrier in humans and can be responsible 318 for similar mechanisms. However, since IA-therapy does not address the source of 319 the soluble spike protein, the ongoing production of spike protein due to persistent 320 infection may prevent a beneficial effect. This would be supported by the fact that the 321 level of spike protein almost returned to its original level shortly after the last IA 322 session. It is also noteworthy that a strong correlation between the amount of all 323 ANSR autoantibodies tested and most pro-inflammatory cytokines was only seen in 324 the spike positive patients, which is only the case for  $\beta 1$  AAB in the spike negative 325 patients. It could be assumed that a persistent infection leads to increased 326 inflammation and generation of auto-reactive antibodies. Moreover, previous studies demonstrated a clear association between inflammation and autoimmunity.<sup>57</sup> 327

Also some changes at the cellular level were observed after IA-therapy. There was a significant reduction in CD4<sup>+</sup> central memory and follicular helper T cells, accompanied by an increase in the frequency of naive T cells. A direct interaction and removal of the cells by the Ig-binding apheresis column can be excluded due to the high specificity of the column.<sup>58</sup> However, the IA procedure might lead to a

It is made available under a CC-BY-NC-ND 4.0 International license .

333 temporary redistribution of T cell subsets within the body. The stress associated with 334 the treatment could trigger a short-term migration of T cells from the bloodstream to 335 various tissues, causing an apparent reduction of these cells in the peripheral blood. 336 Additionally, the observed changes in the cytokine profile, which is fundamental for T 337 cell homeostasis, could impact the maintenance of these T cell populations and result in alterations in the distribution of sub-populations.<sup>59</sup> One difficulty with persistent and 338 339 chronic infections is that ongoing activation induced by constant antigen presence can lead to exhaustion and changes in the differentiation of T cells.<sup>60,61</sup> 340 341 Consequently, it was shown that T cells from post-COVID patients express higher levels of exhaustion markers PD-1. CTLA-4 and Tim-3.62,63 Although this study did 342 not compare the levels of exhaustion markers or the T cell frequencies between post-343 344 COVID patients and convalescent controls, any differences in the frequency of ANSR 345 lysate-specific or spike protein-specific T cells and their PD-1, CTLA-4 and Tim-3 346 expressing T cell subsets before and one month after IA-therapy have been 347 observed. These data suggest that even though these antigens were almost 348 completely removed immediately after therapy, IA-therapy has a short effect on these 349 molecules and obviously no modulating effect on T cells.

The fact that there was no improvement in the patients' perception of their symptoms may also be related to the IA procedure itself. IA-therapy is an invasive procedure that poses a challenge for all patients due to the long duration and use of a Shaldon catheters. Especially for patients in a poor general condition, such as post-COVID patients, this can further increase the level of suffering. In these cases, subjectively reported symptoms may not align with objective measurements

356 This study has some limitations. This is an observational study, and a randomized 357 control trial including a placebo group is needed to verify the beneficial effect of IA-358 therapy. Furthermore, the small sample size of 12 patients reduces the statistical 359 power, potentially masking significant changes. Fortunately, much of the laboratory 360 data is consistent enough among patients to allow reasonably firm conclusions. 361 However, the study does not prove a causal relation between ANSR autoantibodies 362 and ME/CFS symptoms, since IA removes other immunoglobulins as well. Another 363 limitation is a potential practicing effect in the neuropsychological tests. However, it has been shown that these can be eliminated or limited by the selection of tests<sup>64</sup>. 364 365 The follow up at day 30 after IA is relatively short, and it will be necessary to see if

It is made available under a CC-BY-NC-ND 4.0 International license .

the observed improvements are persistent and even lead to a self-assessedimprovement.

368 In summary, this study demonstrates that IA-therapy in patients with post-COVID 369 disease and ME/CSF symptoms leads to a significant reduction in autoantibodies, 370 soluble spike protein, and inflammatory cytokines. This is accompanied by moderate 371 improvements in neuropsychological parameters, though it does not influence the 372 patients' subjective perception of their symptoms. These data lay the foundation for 373 further research to determine the extent of these observed benefits for patients and 374 whether this treatment should be considered standard for post-COVID care in the 375 future.

It is made available under a CC-BY-NC-ND 4.0 International license .

## 376 Methods

#### 377 Study population and design

378 This observational study involved 12 post-COVID patients exhibiting a predominance 379 of ME/CFS symptoms alongside the presence of ANSR autoantibodies ( $\beta 1 > 15$ 380 U/mL;  $\beta 2 > 8$  U/mL; M3 > 6 U/mL; M4 > 10.7 U/mL) and neurological impairments. 381 Age over 18 years, ME/CSF syndrome, the presence of 3 of the 4 ANSR AABs and 382 defined as inclusion criteria. written consent were Patients underwent 383 immunoadsorption therapy and blood samples were collected from patients before 384 the initial session, immediately post-treatment, and again after an additional 30 days 385 (Figure 1). The study was approved by the ethical committee of Ruhr university 386 Bochum (Reg.-Nr. 23-7752) and all participants provided a written informed 387 consents.

#### 388 Immunoadsorption Therapy

Patients underwent a course of TheraSorb - Ig omni 5 adsorber (Miltenyi, Germany)
immunoadsorption therapy comprising 5 sessions over a span of 10 days aimed at
eliminating IgG antibodies. The therapy was carried out at Marien Hospital Herne in
Medical Clinic 1 for Internal Medicine under the supervision of a professional dialysis
unit.

#### 394 **Preparation of PBMCs**

Peripheral blood was collected in S-Monovette K3 EDTA blood collection tubes
(Sarstedt, Germany). Collected blood was pre-diluted in PBS/BSA (Gibco, USA) at a
1:1 ratio and underlaid with 15 mL Ficoll-Paque Plus (GE Healthcare, USA). Tubes
were centrifuged at 800 g for 20 minutes at room temperature. Isolated PBMC were
washed twice with PBS/BSA and stored at -80°C until use as previously described<sup>65</sup>.

#### 400 Antigen stimulation of T cells

401 Isolated PBMC were stimulated with 1µg/ml Sars-CoV-2 OPPs (Miltenyi, Germany), 402 1 µg/mL  $\beta$ 1+ $\beta$ 2 or 1 µg/ml M3+M4 purified cell lysates (Biotrend, Germany). 2.5x10<sup>6</sup> 403 PBMCs were plated for each condition in 96-UWell Plates in RPMI media (Life 404 Technologies), supplemented with 1% Penicillin-Streptomycin-Glutamine (Sigma 405 Aldrich, USA), and 10% FCS (PAN-Biotech, USA) and were stimulated or left 406 untreated as a control for 16 hours. As a positive control, cells were stimulated with 407 SEB (1 µg/ml, Sigma Aldrich, USA) or left untreated as a negative control. After 2

It is made available under a CC-BY-NC-ND 4.0 International license .

hours, Brefeldin A (1µg/ml, Sigma Aldrich, USA) was added. As previously applied by
our groups and others, antigen-specific responses were considered positive after the
non-specific background was subtracted, and more than 0.001% or at least 15
positive cells were detectable. Negative values were set to zero.

#### 412 Measurement of autoantibodies to GPCR

413 Serum was collected in a S-Monovette Serum collection tube (Sarstedt, Germany) 414 and processed per manufacturer's instructions. Purified serum was stored at -20 °C 415 until use. ELISA systems for detection of autoantibodies against β-1 Adrenergic 416 Receptor ( $\beta$ 1),  $\beta$ -2 Adrenergic Receptor ( $\beta$ 2), Muscarinergic Choline Receptor 3 417 (M3), and Muscarinergic Choline Receptor 4 (M4) were all obtained from CellTrend, 418 Germany. Autoantibodies in serum were determined per manufacturer's instructions 419 and normalized using the provided standard. The following cut-offs were used to 420 define presence of autoantibodies:  $\beta_1$ : >15 U/ml;  $\beta_2$ : >8 U/ml; M3: >6 U/ml; M4: 421 >10.7 U/ml.

#### 422 **QPCR measurement of EBV virus titer**

Peripheral blood samples were monitored for EBV by qPCR. DNA was isolated from whole blood samples using AltoStar Purification Kit 1.5 (Altostar, Germany) and qPCR was performed using AltoStar EBV PCR Kit 1.5 following the manufacturer's instructions. Both Kits were performed on an AltoStar AM16 pipetting robot and qPCR was measured on an BioRad C1000 Thermal Cycler. The detection level was determined as the lowest viral load measured within the range of linearity (250 copies/ml).

#### 430 Cytokine analysis

431 Purified serum was stored at -20 °C until use. The level of the cytokines IL-4, IL-2, 432 IP-10 (CXCL10), IL-1β, TNF-α, MCP-1 (CCL2), IL-17A, IL-6, IL-10, IFN-γ, IL-12p70, 433 IL-8 (CXCL8), and TGF- $\beta$ 1 (free active) was assessed using the LEGENDplex 434 Human Essential Immune Response Panel (BioLegend, San Diego, USA) per 435 manufacturers instruction and acquired on a CytoFLEX (Beckman Coulter, Germany) 436 flow cytometer. Briefly, serum was incubated with beads coated with antibodies for 437 one of the analyzed cytokines together with a secondary antibody and phycoerythrin-438 conjugated (PE) detection antibody. Each cytokine is detectable by the bead size and 439 level of allophycocyanin (APC) within the bead, and the intensity of PE is relative to

It is made available under a CC-BY-NC-ND 4.0 International license .

the levels of the cytokine in the sample. The measured fluorescence intensities were

441 normalized using the provided cytokine standard.

#### 442 ME/CFS symptoms and neuropsychological evaluation

443 Long-COVID symptoms were quantified using a 19 items questionnaire based on the 444 ISARIC COVID-19 follow-up study protocol. To quantify the severity of mental and 445 physical fatigue, all patients completed the Chalder fatigue scale, Munich Berlin 446 Symptom Questionnaire (MBSQ) and Epworth Sleepiness Scale (ESS). Physical 447 function and impairment were assessed by the Bell disability scale and the Short 448 Form Health Survey-36 (SF-36). Additionally, hand grip strength was measured as an 449 objective parameter for physical impairment using a hydraulic hand dynamometer 450 (Saehan, Germany). Furthermore, dysautonomic symptoms were evaluated using the 451 COMPASS-31 score. All neuropsychological assessments were conducted using the 452 German version of the "Consortium to Establish a Registry for Alzheimer's Disease 453 Neuropsychological Assessment Battery" (CERAD). The standard assessment, 454 which includes evaluation of verbal fluency (animal naming), a modified version of the 455 Boston Naming Test, global cognition (Mini-Mental State examination), verbal 456 memory (word list learning, delayed recall), as well as constructional practice and 457 delayed recall, was widen out by additional items on processing speed (Trail Making 458 Test A) and executive functioning (Trail Making Test B, letter fluency: S-words).

#### 459 Spike Protein Elisa

Serum was collected in a S-Monovette Serum collection tube (Sarstedt, Germany) and stored at -20 °C until use. The concentration of spike protein was assessed using the Human SARS-CoV.2 RBD Elisa Kit (Invitrogen, Thermo Fisher, USA). The Elisa was performed according to the manufacturers technical manual and no alterations were implemented. The optical density of the plates was determined using a Asys UVM 340.

#### 466 Antibodies

Antigen specific T cells (all antibodies are from BioLegend (USA) unless otherwise
noted): Surface staining: CCR7 (CD197)-PerCP-Cy5.5; clone: G043H7, CD4-A700;
clone: OKT4, LD eFluor780 (eBioscience, USA), CD8-V500; clone: RPA-T8 (BD
Biosciences), CD45RA-BV605; clone: HI100. Intracellular staining: CD137 (4-1BB)PE-Cy7; clone: 4B4-1, CD154 (CD40L)-A647; clone: 24-31, TNFa-eFluor450; clone:
MAb11 (eBioscience, USA), CD3-BV785; clone: OKT3, PD-1-PE; clone: A17188A,

It is made available under a CC-BY-NC-ND 4.0 International license .

- 473 Tim-3-VioBright-Fitc; clone: REA635 (Miltenyi, Germany), CTLA-4-BV421; clone:
- 474 BNI3, Lag-3-BV650; clone: 11C3C65. Fixable Viability Dye eFluor 780 (eBioscience,
- 475 USA) was used for live/dead discrimination.

#### 476 Flow Cytometry

477 Stimulated PBMC were extracellular stained with optimal concentrations of antibodies 478 for 10 minutes at room temperature in the dark. Cells were washed twice with 479 PBS/BSA before preparation for intracellular staining using the Intracellular Fixation & 480 Permeabilization Buffer Set (Thermo Fisher Scientific) as per manufacturer's 481 instructions. Fixed and permeabilized cells were stained for 30 minutes at room 482 temperature in the dark with an optimal dilution of antibodies against the intracellular 483 antigen.

All samples were immediately acquired on a CytoFlex flow cytometer (Beckman Coulter). Quality control was performed daily using the recommended CytoFlex Daily QC Fluorospheres (Beckman Coulter). No modification to the compensation matrices was required throughout the study. Flow cytometry data were analyzed using FlowJo version 10.6.2 (BD Biosciences); gating strategies are presented in Supplemental Figures S5+S6.

#### 490 Statistical analysis

491 Statistical analysis was performed using R, version 4.2.1. Categorical variables are 492 summarized as numbers and frequencies; quantitative variables are reported as 493 mean ± SD. No data transformation was used. Violin plots depict the median and the 494 first and third quartiles. The whiskers correspond to 1.5 times the interquartile range. 495 All applied statistical tests are paired and two-sided. Dotted lines between violins 496 indicate the individual patients. Differences in quantitative variables between all three 497 groups are analyzed using non-parametric Wilcoxon test. P values below 0.050 were 498 considered significant. P values were not corrected for multiple testing, as this study was of exploratory nature<sup>66,67</sup>. The normalization standard for the ELISA results was 499 500 calculated using a four parameter logistic regression. Parameter correlation was 501 assessed using Spearman's rank correlation coefficient.

It is made available under a CC-BY-NC-ND 4.0 International license .

#### 502 Author contributions

Conceptualization: T.W. and N.B.; Data curation: M.A., L.W., K.R. and U.S.; Formal
analysis: M.A., L.W., K.R. and U.S.; Funding acquisition: N.B.; Investigation: M.A.,
L.W., K.R., S.S., J.K., S.K., U.S. and N.B.; Methodology: M.A., U.S. and N.B.;
Resources: A.D., F.S. and T.W.; Visualization: M.A. and K.R.; Writing – original draft:
M.A., L.W., K.R., U.S. and N.B.; Writing - review & editing: M.A., L.W., K.R., U.S. and
N.B.;

#### 509 Acknowledgments

510 We want to express our deepest gratitude to the patients who donated their blood 511 samples and clinical data for this project. We thank Miltenyi Biotec who supported our 512 study by providing materials and equipment (TheraSorb columns) for 513 Immunoadsorption. This work was further supported by DFG grants NFDI4 514 (501875662)

#### 515 **Conflict of interest**

516 The study was initiated by the investigators themselves. They independently created 517 the study without any external guidance or involvement from entities like Miltenyi 518 Biotec or any other undisclosed parties, pertaining to its design, analysis, data 519 interpretation or manuscript approval. The authors themself did not receive any 520 payment related to this study and have stated that they have no conflicting interests.

It is made available under a CC-BY-NC-ND 4.0 International license .

#### 521 **References**

- Davis, H.E., McCorkell, L., Vogel, J.M., and Topol, E.J. (2023). Long COVID: major findings, mechanisms and recommendations. Nat. Rev. Microbiol. 21, 133– 146. https://doi.org/10.1038/s41579-022-00846-2.
- 525 2. Carfì, A., Bernabei, R., Landi, F., and for the Gemelli Against COVID-19 Post526 Acute Care Study Group (2020). Persistent Symptoms in Patients After Acute
  527 COVID-19. JAMA *324*, 603. https://doi.org/10.1001/jama.2020.12603.
- Ramadan, M.S., Bertolino, L., Zampino, R., Durante-Mangoni, E., Durante-Mangoni, E., Iossa, D., Bertolino, L., Ursi, M.P., D'Amico, F., Karruli, A., et al. (2021). Cardiac sequelae after coronavirus disease 2019 recovery: a systematic review. Clin. Microbiol. Infect. 27, 1250–1261. https://doi.org/10.1016/j.cmi.2021.06.015.
- 4. Carvalho-Schneider, C., Laurent, E., Lemaignen, A., Beaufils, E., Bourbao-533 Tournois, C., Laribi, S., Flament, T., Ferreira-Maldent, N., Bruyère, F., Stefic, K., 534 535 et al. (2021). Follow-up of adults with noncritical COVID-19 two months after 536 symptom onset. Clin. Microbiol. Infect. 258-263. 27, 537 https://doi.org/10.1016/i.cmi.2020.09.052.
- 5. Daines, L., Zheng, B., Elneima, O., Harrison, E., Lone, N.I., Hurst, J.R., Brown,
   J.S., Sapey, E., Chalmers, J.D., Quint, J.K., et al. (2023). Characteristics and risk
   factors for post-COVID-19 breathlessness after hospitalisation for COVID-19.
   ERJ Open Res. *9*, 00274–02022. https://doi.org/10.1183/23120541.00274-2022.
- Jaywant, A., Gunning, F.M., Oberlin, L.E., Santillana, M., Ognyanova, K.,
   Druckman, J.N., Baum, M.A., Lazer, D., and Perlis, R.H. (2024). Cognitive
   Symptoms of Post–COVID-19 Condition and Daily Functioning. JAMA Netw.
   Open 7, e2356098. https://doi.org/10.1001/jamanetworkopen.2023.56098.
- 546 7. Li, Z., Zhang, Z., Zhang, Z., Wang, Z., and Li, H. (2023). Cognitive impairment
  547 after long COVID-19: current evidence and perspectives. Front. Neurol. 14.
  548 https://doi.org/10.3389/fneur.2023.1239182.
- 8. Quan, M., Wang, X., Gong, M., Wang, Q., Li, Y., and Jia, J. (2023). Post-COVID cognitive dysfunction: current status and research recommendations for high risk population. Lancet Reg. Health West. Pac. 38. https://doi.org/10.1016/j.lanwpc.2023.100836.
- Sotzny, F., Filgueiras, I.S., Kedor, C., Freitag, H., Wittke, K., Bauer, S., Sepúlveda, N., Mathias da Fonseca, D.L., Baiocchi, G.C., Marques, A.H.C., et al. (2022). Dysregulated autoantibodies targeting vaso- and immunoregulatory receptors in Post COVID Syndrome correlate with symptom severity. Front. Immunol. *13*, 981532. https://doi.org/10.3389/fimmu.2022.981532.
- 10. Iwasaki, A., and Putrino, D. (2023). Why we need a deeper understanding of the
  pathophysiology of long COVID. Lancet Infect. Dis. 23, 393–395.
  https://doi.org/10.1016/S1473-3099(23)00053-1.
- 11. Machkovech, H.M., Hahn, A.M., Wang, J.G., Grubaugh, N.D., Halfmann, P.J.,
  Johnson, M.C., Lemieux, J.E., O'Connor, D.H., Piantadosi, A., Wei, W., et al.
  (2024). Persistent SARS-CoV-2 infection: significance and implications. Lancet
  Infect. Dis. 24, e453–e462. https://doi.org/10.1016/S1473-3099(23)00815-0.
- 565 12. Ghafari, M., Hall, M., Golubchik, T., Ayoubkhani, D., House, T., MacIntyre566 Cockett, G., Fryer, H.R., Thomson, L., Nurtay, A., Kemp, S.A., et al. (2024).
  567 Prevalence of persistent SARS-CoV-2 in a large community surveillance study.
  568 Nature 626, 1094–1101. https://doi.org/10.1038/s41586-024-07029-4.
- 569 13. Tejerina, F., Catalan, P., Rodriguez-Grande, C., Adan, J., Rodriguez-Gonzalez,
  570 C., Muñoz, P., Aldamiz, T., Diez, C., Perez, L., Fanciulli, C., et al. (2022). Post571 COVID-19 syndrome. SARS-CoV-2 RNA detection in plasma, stool, and urine in

572 patients with persistent symptoms after COVID-19. BMC Infect. Dis. 22, 211. 573 https://doi.org/10.1186/s12879-022-07153-4.

- 14. Ceulemans, L.J., Khan, M., Yoo, S.-J., Zapiec, B., Van Gerven, L., Van Slambrouck, J., Vanstapel, A., Van Raemdonck, D., Vos, R., Wauters, E., et al. (2021). Persistence of SARS-CoV-2 RNA in lung tissue after mild COVID-19. Lancet Respir. Med. *9*, e78–e79. https://doi.org/10.1016/S2213-2600(21)00240-578 X.
- 579 15. Craddock, V., Mahajan, A., Spikes, L., Krishnamachary, B., Ram, A.K., Kumar, 580 A., Chen, L., Chalise, P., and Dhillon, N.K. (2023). Persistent Circulation of 581 Soluble and Extracellular vesicle-linked Spike Protein in Individuals with Post-582 Med. Acute Sequelae of COVID-19. J. Virol. 95. e28568. https://doi.org/10.1002/jmv.28568. 583
- 16. Craddock, V., Mahajan, A., Krishnamachary, B., Spikes, L., Chalise, P., and Dhillon, N.K. (2022). Persistent Presence of Spike protein and Viral RNA in the Circulation of Individuals with Post-Acute Sequelae of COVID-19. Preprint at medRxiv, https://doi.org/10.1101/2022.08.07.22278520.
- 589 17. Swank, Z., Senussi, Y., Manickas-Hill, Z., Yu, X.G., Li, J.Z., Alter, G., and Walt,
  590 D.R. (2023). Persistent Circulating Severe Acute Respiratory Syndrome
  591 Coronavirus 2 Spike Is Associated With Post-acute Coronavirus Disease 2019
  592 Sequelae. Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am. 76, e487–e490.
  593 https://doi.org/10.1093/cid/ciac722.
- 59418. Su, Y., Yuan, D., Chen, D.G., Ng, R.H., Wang, K., Choi, J., Li, S., Hong, S.,595Zhang, R., Xie, J., et al. (2022). Multiple early factors anticipate post-acute596COVID-19597https://doi.org/10.1016/j.cell.2022.01.014.
- 598 19. Dobrowolska, K., Zarębska-Michaluk, D., Poniedziałek, B., Jaroszewicz, J.,
  599 Flisiak, R., and Rzymski, P. (2023). Overview of autoantibodies in COVID-19
  600 convalescents. J. Med. Virol. *95*, e28864. https://doi.org/10.1002/jmv.28864.
- 20. Seibert, F.S., Stervbo, U., Wiemers, L., Skrzypczyk, S., Hogeweg, M., Bertram, 601 602 S., Kurek, J., Anft, M., Westhoff, T.H., and Babel, N. (2023). Severity of 603 neurological Long-COVID symptoms correlates with increased level of 604 autoantibodies targeting vasoregulatory and autonomic nervous system 605 Autoimmun. Rev. receptors. 22. 103445. 606 https://doi.org/10.1016/j.autrev.2023.103445.
- 21. Zubchenko, S., Kril, I., Nadizhko, O., Matsyura, O., and Chopyak, V. (2022).
  Herpesvirus infections and post-COVID-19 manifestations: a pilot observational study. Rheumatol. Int. *42*, 1523–1530. https://doi.org/10.1007/s00296-022-051469.
- 611 22. Elizalde-Díaz, J.P., Miranda-Narváez, C.L., Martínez-Lazcano, J.C., and
  612 Martínez-Martínez, E. (2022). The relationship between chronic immune
  613 response and neurodegenerative damage in long COVID-19. Front. Immunol. *13*,
  614 1039427. https://doi.org/10.3389/fimmu.2022.1039427.
- 815 23. Nlandu, Y., Tannor, E.K., Bafemika, T., and Makulo, J.-R. (2024). Kidney damage
  816 associated with COVID-19: from the acute to the chronic phase. Ren. Fail. *46*,
  817 2316885. https://doi.org/10.1080/0886022X.2024.2316885.
- 24. Rizvi, A.A., Kathuria, A., Mahmeed, W.A., Al-Rasadi, K., Al-Alawi, K., Banach, M.,
  Banerjee, Y., Ceriello, A., Cesur, M., Cosentino, F., et al. (2022). Post-COVID
  syndrome, inflammation, and diabetes. J. Diabetes Complications *36*, 108336.
  https://doi.org/10.1016/j.jdiacomp.2022.108336.

25. Pretorius, E., Venter, C., Laubscher, G.J., Kotze, M.J., Oladejo, S.O., Watson,
L.R., Rajaratnam, K., Watson, B.W., and Kell, D.B. (2022). Prevalence of
symptoms, comorbidities, fibrin amyloid microclots and platelet pathology in
individuals with Long COVID/Post-Acute Sequelae of COVID-19 (PASC).
Cardiovasc. Diabetol. *21*, 148. https://doi.org/10.1186/s12933-022-01579-5.

- 627 26. Charfeddine, S., Ibn Hadj Amor, H., Jdidi, J., Torjmen, S., Kraiem, S., Hammami, 628 R., Bahloul, A., Kallel, N., Moussa, N., Touil, I., et al. (2021). Long COVID 19 629 Syndrome: Is It Related to Microcirculation and Endothelial Dysfunction? Insights 630 From TUN-EndCOV Study. Front. Cardiovasc. Med. 745758. 8. 631 https://doi.org/10.3389/fcvm.2021.745758.
- 27. Tölle, M., Freitag, H., Antelmann, M., Hartwig, J., Schuchardt, M., van der Giet,
  M., Eckardt, K.-U., Grabowski, P., and Scheibenbogen, C. (2020). Myalgic
  Encephalomyelitis/Chronic Fatigue Syndrome: Efficacy of Repeat
  Immunoadsorption. J. Clin. Med. *9*, 2443. https://doi.org/10.3390/jcm9082443.
- 636 28. Scheibenbogen, C., Loebel, M., Freitag, H., Krueger, A., Bauer, S., Antelmann, 637 M., Doehner, W., Scherbakov, N., Heidecke, H., Reinke, P., et al. (2018). 638 Immunoadsorption to remove ß2 adrenergic receptor antibodies in Chronic 639 Fatigue Syndrome CFS/ME. PLoS ONE 13, e0193672. 640 https://doi.org/10.1371/journal.pone.0193672.
- Stein, E., Heindrich, C., Wittke, K., Kedor, C., Kim, L., Freitag, H., Krüger, A.,
  Tölle, M., and Scheibenbogen, C. (2023). Observational Study of Repeat
  Immunoadsorption (RIA) in Post-COVID ME/CFS Patients with Elevated ß2Adrenergic Receptor Autoantibodies—An Interim Report. J. Clin. Med. *12*, 6428.
  https://doi.org/10.3390/jcm12196428.
- 30. Gao, Z., Feng, Y., Xu, J., and Liang, J. (2022). T-cell exhaustion in immunemediated inflammatory diseases: New implications for immunotherapy. Front.
  Immunol. *13*, 977394. https://doi.org/10.3389/fimmu.2022.977394.
- 31. Luo, Q., Ye, J., Zeng, L., Luo, Z., Deng, Z., Li, X., Guo, Y., Huang, Z., and Li, J.
  (2017). Elevated expression of PD<sup>1</sup> on T cells correlates with disease activity in rheumatoid arthritis. Mol. Med. Rep. https://doi.org/10.3892/mmr.2017.8204.
- 32. Cabral-Marques, O., and Riemekasten, G. (2017). Functional autoantibodies
  targeting G protein-coupled receptors in rheumatic diseases. Nat. Rev.
  Rheumatol. *13*, 648–656. https://doi.org/10.1038/nrrheum.2017.134.
- 33. Karschnia, M., Zweck, E., Scheiber, D., Heidecke, H., Barthuber, C., Kelm, M.,
  Roden, M., Westenfeld, R., Szendroedi, J., and Boege, F. (2022). Associations of
  GPCR autoantibodies with clinical, histological, metabolic and hemodynamic
  features in non-ischemic heart failure patients. Eur. Heart J. *43*, ehac544.757.
  https://doi.org/10.1093/eurheartj/ehac544.757.
- 34. Wallukat, G., and Schimke, I. (2014). Agonistic autoantibodies directed against Gprotein-coupled receptors and their relationship to cardiovascular diseases.
  Semin. Immunopathol. *36*, 351–363. https://doi.org/10.1007/s00281-014-0425-9.
- 35. Wallukat, G., Hohberger, B., Wenzel, K., Fürst, J., Schulze-Rothe, S., Wallukat,
  A., Hönicke, A.-S., and Müller, J. (2021). Functional autoantibodies against Gprotein coupled receptors in patients with persistent Long-COVID-19 symptoms.
  J. Transl. Autoimmun. *4*, 100100. https://doi.org/10.1016/j.jtauto.2021.100100.
- 36. Cabral-Marques, O., Halpert, G., Schimke, L.F., Ostrinski, Y., Vojdani, A.,
  Baiocchi, G.C., Freire, P.P., Filgueiras, I.S., Zyskind, I., Lattin, M.T., et al. (2022).
  Autoantibodies targeting GPCRs and RAS-related molecules associate with
  COVID-19 severity. Nat. Commun. *13*, 1220. https://doi.org/10.1038/s41467-02228905-5.

- 672 37. Cabral-Marques, O., Halpert, G., Schimke, L.F., Ostrinski, Y., Zyskind, I., Lattin, 673 M.T., Tran, F., Schreiber, S., Margues, A.H.C., Filgueiras, I.S., et al. (2021). The 674 relationship between autoantibodies targeting GPCRs and the renin-angiotensin 675 system associates with COVID-19 severity. Preprint medRxiv. at 676 https://doi.org/10.1101/2021.08.24.21262385
- 677 https://doi.org/10.1101/2021.08.24.21262385.
- 38. Hall, J., Bourne, K.M., Vernino, S., Hamrefors, V., Kharraziha, I., Nilsson, J.,
  Sheldon, R.S., Fedorowski, A., and Raj, S.R. (2022). Detection of G Protein–
  Coupled Receptor Autoantibodies in Postural Orthostatic Tachycardia Syndrome
  Using Standard Methodology. Circulation 146, 613–622.
  https://doi.org/10.1161/CIRCULATIONAHA.122.059971.
- 683 39. Kwan, A.C., Ebinger, J.E., Wei, J., Le, C.N., Oft, J.R., Zabner, R., Teodorescu, 684 D., Botting, P.G., Navarrette, J., Ouyang, D., et al. (2022). Apparent risks of 685 postural orthostatic tachycardia syndrome diagnoses after COVID-19 vaccination 686 SARS-Cov-2 Infection. Cardiovasc. Res. 1. 1187-1194. and Nat. 687 https://doi.org/10.1038/s44161-022-00177-8.
- 40. Mallick, D., Goyal, L., Chourasia, P., Zapata, M.R., Yashi, K., and Surani, S.
  (2023). COVID-19 Induced Postural Orthostatic Tachycardia Syndrome (POTS):
  A Review. Cureus *15*, e36955. https://doi.org/10.7759/cureus.36955.
- 41. Kedor, C., Freitag, H., Meyer-Arndt, L., Wittke, K., Hanitsch, L.G., Zoller, T.,
  Steinbeis, F., Haffke, M., Rudolf, G., Heidecker, B., et al. (2022). A prospective
  observational study of post-COVID-19 chronic fatigue syndrome following the first
  pandemic wave in Germany and biomarkers associated with symptom severity.
  Nat. Commun. *13*, 5104. https://doi.org/10.1038/s41467-022-32507-6.
- 42. Ruhe, J., Giszas, B., Schlosser, M., Reuken, P.A., Wolf, G., and Stallmach, A.
  (2023). Immune adsorption for the treatment of fatigue-dominant long-/post-COVID syndrome. Dtsch. Ärztebl. Int. https://doi.org/10.3238/arztebl.m2023.0073.
- 43. Hohberger, B., Harrer, T., Mardin, C., Kruse, F., Hoffmanns, J., Rogge, L.,
  Heltmann, F., Moritz, M., Szewczykowski, C., Schottenhamml, J., et al. (2021).
  Case Report: Neutralization of Autoantibodies Targeting G-Protein-Coupled
  Receptors Improves Capillary Impairment and Fatigue Symptoms After COVID19 Infection. Front. Med. *8*, 754667. https://doi.org/10.3389/fmed.2021.754667.
- 44. Wu, X., Chen, J., Wu, M., and Zhao, J.X. (2015). Aptamers: Active Targeting
  Ligands for Cancer Diagnosis and Therapy. Theranostics *5*, 322–344.
  https://doi.org/10.7150/thno.10257.
- 45. Daha, N.A., Banda, N.K., Roos, A., Beurskens, F.J., Bakker, J.M., Daha, M.R.,
  and Trouw, L.A. (2011). Complement activation by (auto-) antibodies. Mol.
  Immunol. 48, 1656–1665. https://doi.org/10.1016/j.molimm.2011.04.024.
- 46. Mathsson, L., Ahlin, E., Sjöwall, C., Skogh, T., and Rönnelid, J. (2007). Cytokine
  induction by circulating immune complexes and signs of in-vivo complement
  activation in systemic lupus erythematosus are associated with the occurrence of
  anti-Sjögren's syndrome A antibodies. Clin. Exp. Immunol. 147, 513–520.
  https://doi.org/10.1111/j.1365-2249.2006.03313.x.
- 47. Nielsen, C.H., and Bendtzen, K. (2012). Immunoregulation by naturally occurring and disease-associated autoantibodies : binding to cytokines and their role in regulation of T-cell responses. Adv. Exp. Med. Biol. 750, 116–132. https://doi.org/10.1007/978-1-4614-3461-0\_9.
- 48. Ku, C.-L., Chi, C.-Y., Bernuth, H. von, and Doffinger, R. (2020). Autoantibodies
  against cytokines: phenocopies of primary immunodeficiencies? Hum. Genet.
  139, 783. https://doi.org/10.1007/s00439-020-02180-0.

- 49. Cheng, A., and Holland, S.M. (2024). Anti-cytokine autoantibodies: mechanistic
  insights and disease associations. Nat. Rev. Immunol. 24, 161–177.
  https://doi.org/10.1038/s41577-023-00933-2.
- 50. Karin, N. (2018). Autoantibodies to Chemokines and Cytokines Participate in the
  Regulation of Cancer and Autoimmunity. Front. Immunol. *9*, 623.
  https://doi.org/10.3389/fimmu.2018.00623.
- 51. Barzilai, O., Ram, M., and Shoenfeld, Y. (2007). Viral infection can induce the
  production of autoantibodies. Curr. Opin. Rheumatol. *19*, 636–643.
  https://doi.org/10.1097/BOR.0b013e3282f0ad25.
- 52. Ludewig, B., Krebs, P., Metters, H., Tatzel, J., Türeci, Ö., and Sahin, U. (2004).
  Molecular Characterization of Virus-induced Autoantibody Responses. J. Exp.
  Med. 200, 637–646. https://doi.org/10.1084/jem.20040358.
- 53. Riddell, M.A., Moss, W.J., Hauer, D., Monze, M., and Griffin, D.E. (2007). Slow
  clearance of measles virus RNA after acute infection. J. Clin. Virol. Off. Publ. Pan
  Am. Soc. Clin. Virol. 39, 312–317. https://doi.org/10.1016/j.jcv.2007.05.006.
- 54. Varkey, J.B., Shantha, J.G., Crozier, I., Kraft, C.S., Lyon, G.M., Mehta, A.K.,
  Kumar, G., Smith, J.R., Kainulainen, M.H., Whitmer, S., et al. (2015). Persistence
  of Ebola Virus in Ocular Fluid during Convalescence. N. Engl. J. Med. *372*, 2423–
  2427. https://doi.org/10.1056/NEJMoa1500306.
- 741 55. Grobbelaar, L.M., Venter, C., Vlok, M., Ngoepe, M., Laubscher, G.J., Lourens, 742 P.J., Steenkamp, J., Kell, D.B., and Pretorius, E. (2021). SARS-CoV-2 spike 743 protein S1 induces fibrin(ogen) resistant to fibrinolysis: implications for microclot 744 COVID-19. formation in Biosci. Rep. 41. BSR20210611. 745 https://doi.org/10.1042/BSR20210611.
- 56. Fontes-Dantas, F.L., Fernandes, G.G., Gutman, E.G., De Lima, E.V., Antonio,
  L.S., Hammerle, M.B., Mota-Araujo, H.P., Colodeti, L.C., Araújo, S.M.B., Froz,
  G.M., et al. (2023). SARS-CoV-2 Spike protein induces TLR4-mediated long-term
  cognitive dysfunction recapitulating post-COVID-19 syndrome in mice. Cell Rep.
  42, 112189. https://doi.org/10.1016/j.celrep.2023.112189.
- 57. Xiang, Y., Zhang, M., Jiang, D., Su, Q., and Shi, J. (2023). The role of
  inflammation in autoimmune disease: a therapeutic target. Front. Immunol. *14*.
  https://doi.org/10.3389/fimmu.2023.1267091.
- 58. C, S., F, K., L, P. da S., C, N., M, S., Le, B., K, K., J, B., C, S., A, L., et al. (2019).
  Effectiveness of different immunoadsorption columns for anti-A/B antibody
  depletion. Atheroscler. Suppl. 40.
  https://doi.org/10.1016/j.atherosclerosissup.2019.08.030.
- 757 https://doi.org/10.1016/j.atheroscierosissup.2019.08.030.
- 59. Woodland, D.L., and Kohlmeier, J.E. (2009). Migration, maintenance and recall of
  memory T cells in peripheral tissues. Nat. Rev. Immunol. *9*, 153–161.
  https://doi.org/10.1038/nri2496.
- 60. Kahan, S.M., Wherry, E.J., and Zajac, A.J. (2015). T Cell Exhaustion During
  Persistent Viral Infections. Virology 0, 180–193.
  https://doi.org/10.1016/j.virol.2014.12.033.
- 61. Saeidi, A., Zandi, K., Cheok, Y.Y., Saeidi, H., Wong, W.F., Lee, C.Y.Q., Cheong, 764 765 H.C., Yong, Y.K., Larsson, M., and Shankar, E.M. (2018). T-Cell Exhaustion in 766 Chronic Infections: Reversing the State of Exhaustion and Reinvigorating Optimal 767 Protective Immune Responses. Front. Immunol. 9. 2569. 768 https://doi.org/10.3389/fimmu.2018.02569.
- 62. Klein, J., Wood, J., Jaycox, J.R., Dhodapkar, R.M., Lu, P., Gehlhausen, J.R.,
  Tabachnikova, A., Greene, K., Tabacof, L., Malik, A.A., et al. (2023).
  Distinguishing features of long COVID identified through immune profiling. Nature
  623, 139–148. https://doi.org/10.1038/s41586-023-06651-y.

- 63. Yin, K., Peluso, M.J., Luo, X., Thomas, R., Shin, M.-G., Neidleman, J., Andrew,
  A., Young, K., Ma, T., Hoh, R., et al. (2023). Long COVID manifests with T cell
  dysregulation, inflammation, and an uncoordinated adaptive immune response to
  SARS-CoV-2. BioRxiv Prepr. Serv. Biol., 2023.02.09.527892.
  https://doi.org/10.1101/2023.02.09.527892.
- 64. Goldberg, T.E., Harvey, P.D., Wesnes, K.A., Snyder, P.J., and Schneider, L.S.
  (2015). Practice effects due to serial cognitive assessment: Implications for
  preclinical Alzheimer's disease randomized controlled trials. Alzheimers Dement.
  Diagn. Assess. Dis. Monit. 1, 103–111.
  https://doi.org/10.1016/j.dadm.2014.11.003.
- 65. Nienen, M., Štervbo, U., Mölder, F., Kaliszczyk, S., Kuchenbecker, L., Gayova, L., 783 784 Schweiger, B., Jürchott, K., Hecht, J., Neumann, A.U., et al. (2019). The Role of 785 pre-existing cross-reactive central memory CD4 T-cells in vaccination with 786 previously Immunol. unseen influenza strains. Front. 10. 593. 787 https://doi.org/10.3389/fimmu.2019.00593.
- 66. Bender, R., and Lange, S. (2001). Adjusting for multiple testing—when and how?
  J. Clin. Epidemiol. *54*, 343–349. https://doi.org/10.1016/S0895-4356(00)00314-0.
- 67. Li, G., Taljaard, M., Van Den Heuvel, E.R., Levine, M.Ah., Cook, D.J., Wells,
  G.A., Devereaux, P.J., and Thabane, L. (2016). An introduction to multiplicity
  issues in clinical trials: the what, why, when and how. Int. J. Epidemiol., dyw320.
  https://doi.org/10.1093/ije/dyw320.

It is made available under a CC-BY-NC-ND 4.0 International license .

# 795 Figures and Tables:

#### 796 Table 1. Cohort statistics

Patients (n)	12
Age (Median [Q1-Q3])	50 [34.5-60]
Sex (Female; n (%))	8 (66.7%)
BMI (Median [Q1-Q3])	25.25 [22.1-26.9]
ME/CSF	12 (100%)
- Trigger SARS-CoV-2 infection	4 (33.3%)
- Other trigger, worsened by SARS-CoV-2	8 (66.6%)
infection	
Comorbidities	
Arterial hypertension (n (%))	3 (25.0%)
Hyperlipidemia (n (%))	3 (25.0%)
COPD (n (%))	2 (16.7%)
Nicotine abuse (n (%))	2 (16.7%)
ESRD (n (%))	0 (0%)
Diabetes mellitus (n (%))	0 (0%)
	1 4 41 1 11

797 BMI = Body mass index; COPD = chronic obstructive pulmonary disease; ESRD =

798 End stage renal disease

It is made available under a CC-BY-NC-ND 4.0 International license .

#### 800 Table 2 Reported symptoms, and self-rated physical and mental health

Self rated physical and mental health           SF-36 questionary           SF-36-Total Score (Mean (SD))         29,7 (7.2)         31,7           Physical health         Physical functioning (Mean (SD))         29,2 (16.2)         29,1           Role-physical (Mean (SD))         8,3 (15.6)         2,3           Mental health         Mental health         60,7           Vitality (Mean (SD))         51,7 (14.1)         60,7           Vitality (Mean (SD))         13,9 (13.19         15,5           Role-emotional (Mean (SD))         66,6 (43.1)         81,6           Social functioning (Mean (SD))         13,4 (14)         17 (           General health (Mean (SD))         22 $\pm$ (2)         22,7           Bodily pain (Mean (SD))         28,6 (27)         36,2           Other questionaries         7         7           Chalder Fatigue Scale (bm) (Mean (SD))         10,3 (0.9)         9,2           Bell Score (Mean (SD))         30 (7.4)         31,5           Canadian criteria for ME/CFS (n (%))         10/11 (90.9%)         9/11           neurological/congnitive manifestations (n (%))         11/11 (100%)         10/11           Persistent cough (n (%))         10/11 (90.9%)         8/11           Tiredness (n (%))         11/11 (	nth)	-Value
SF-36 questionary       29,7 (7.2)       31,7         Physical health       Physical functioning (Mean (SD))       29,2 (16.2)       29,1         Role-physical (Mean (SD))       8,3 (15.6)       2,3         Mental health       Mental health       60,7         Mental health (Mean (SD))       51,7 (14.1)       60,7         Vitality (Mean (SD))       13,9 (13.19       15,5         Role-emotional (Mean (SD))       66,6 (43.1)       81,6         Social functioning (Mean (SD))       13,4 (14)       17 (         General health (Mean (SD))       22 $\pm$ (2)       22,7         Bodily pain (Mean (SD))       28,6 (27)       36,2         Other questionaries       Chalder Fatigue Scale (bm) (Mean (SD))       10.3 (0.9)       9.2         Bell Score (Mean (SD))       30 (7.4)       31,6         Canadian criteria for ME/CFS (n (%))       10/11 (90.9%)       10/11         neurological/congnitive manifestations (n (%))       11/11 (100%)       11/1         Self reported symptoms       Flu-like symptoms (n (%))       10/11 (90.9%)       8/11         Tiredness (n (%))       11/11 (10%)       11/1       10%)       11/1         Odor changes (n (%))       2/11 (18.2%)       1/11         Changes in taste (n (%)) <td< td=""><td></td><td></td></td<>		
SF36-Total Score (Mean (SD)) $29,7 (7.2)$ $31,7$ Physical health         Physical functioning (Mean (SD)) $29,2 (16.2)$ $29,1$ Role-physical (Mean (SD)) $8,3 (15.6)$ $2,3$ Mental health         Mental health $60,7$ Vitality (Mean (SD)) $51,7 (14.1)$ $60,7$ Vitality (Mean (SD)) $51,7 (14.1)$ $60,7$ Note-emotional (Mean (SD)) $51,7 (14.1)$ $60,7$ Role-emotional (Mean (SD)) $51,7 (14.1)$ $60,7$ Social functioning (Mean (SD)) $13,9 (13.19$ $15,5$ Social functioning (Mean (SD)) $13,4 (14)$ $17(1)$ General health (Mean (SD)) $22 \pm (2)$ $22,7$ Bodily pain (Mean (SD)) $28,6 (27)$ $36,6,2$ Other questionaries $Chalder Fatigue Scale (bm) (Mean (SD))$ $10/11 (90.9\%)$ $9,12$ Bell Score (Mean (SD)) $30 (7.4)$ $31,6$ $30 (7.4)$ $31,6$ Canadian criteria for ME/CFS (n (%)) $10/11 (90.9\%)$ $10/11$ $100\%$ $10/11$ Memological manifestations (n (%)) $10/11 (90.9\%)$		
Physical health           Physical functioning (Mean (SD))         29,2 (16.2)         29,1           Role-physical (Mean (SD))         8,3 (15.6)         2,3           Mental health             Mental health (Mean (SD))         51,7 (14.1)         60,7           Vitality (Mean (SD))         13,9 (13.19         15,5           Role-emotional (Mean (SD))         66,6 (43.1)         81,6           Social functioning (Mean (SD))         13,4 (14)         17 (           General health (Mean (SD))         22 $\pm$ (2)         22,7           Bodily pain (Mean (SD))         28,6 (27)         36,2           Other questionaries             Chalder Fatigue Scale (bm) (Mean (SD))         10,3 (0.9)         9,2           Bell Score (Mean (SD))         30 (7.4)         31,8           Canadian criteria for ME/CFS (n (%))         10/11 (90.9%)         9/11           neurological/congnitive manifestations (n (%))         11/11 (100%)         11/11           Self reported symptoms          10/11 (90.9%)         8/11           Flu-like symptoms (n (%))         10/11 (90.9%)         11/11         10/11 (90.9%)         11/11           Dyspnoe (n (%))         1/11 (100%)         11/11         11/11	' (11.9) C	).57 <sup>¥</sup>
Physical functioning (Mean (SD))         29,2 (16.2)         29,1           Role-physical (Mean (SD))         8,3 (15.6)         2,3           Mental health             Mental health (Mean (SD))         51,7 (14.1)         60,7           Vitality (Mean (SD))         13,9 (13.19         15,5           Role-emotional (Mean (SD))         66,6 (43.1)         81,8           Social functioning (Mean (SD))         13,4 (14)         17 (           General health (Mean (SD))         22 ± (2)         22,7           Bodily pain (Mean (SD))         28,6 (27)         36,2           Other questionaries             Chalder Fatigue Scale (bm) (Mean (SD))         10,3 (0.9)         9,2           Bell Score (Mean (SD))         30 (7.4)         31,8           Canadian criteria for ME/CFS (n (%))         10/11 (90.9%)         9/11           neurological/congnitive manifestations (n (%))         11/11 (100%)         11/11           Self reported symptoms          10/11 (90.9%)         8/11           Flu-like symptoms (n (%))         10/11 (90.9%)         8/11         11/11           Dyspnoe (n (%))         10/11 (90.9%)         8/11         11/11           Dyspnoe (n (%))         2/11 (18.2%)		
Role-physical (Mean (SD))         8,3 (15.6)         2,3           Mental health         Mental health (Mean (SD))         51,7 (14.1)         60,7           Vitality (Mean (SD))         13,9 (13.19         15,5           Role-emotional (Mean (SD))         66,6 (43.1)         81,5           Social functioning (Mean (SD))         13,4 (14)         17 (           General health (Mean (SD))         22 ± (2)         22,7           Bodily pain (Mean (SD))         28,6 (27)         36,2           Other questionaries         C         24,6 (27)         36,2           Chalder Fatigue Scale (bm) (Mean (SD))         10.3 (0.9)         9,2           Bell Score (Mean (SD))         30 (7.4)         31,8           Canadian criteria for ME/CFS (n (%))         10/11 (90.9%)         9/11           neurological/congnitive manifestations (n (%))         11/11 (100%)         11/1           Self reported symptoms         Flu-like symptoms (n (%))         10/11 (90.9%)         8/11           Tiredness (n (%))         10/11 (90.9%)         10/11         90.9%)         8/11           Mental health         (%)         11/11 (100%)         11/11         11/11         100%)         11/11           Self reported symptoms         (n (%))         11/11 (90.9%)	(18.8) 0	).67 <sup>¥</sup>
Mental health         Mental health (Mean (SD))         51,7 (14.1)         60,7           Vitality (Mean (SD))         13,9 (13.19         15,5           Role-emotional (Mean (SD))         66,6 (43.1)         81,6           Social functioning (Mean (SD))         13,4 (14)         17 (           General health (Mean (SD))         22 ± (2)         22,7           Bodily pain (Mean (SD))         28,6 (27)         36,2           Other questionaries             Chalder Fatigue Scale (bm) (Mean (SD))         10.3 (0.9)         9,2           Bell Score (Mean (SD))         30 (7.4)         31.5           Canadian criteria for ME/CFS (n (%))         10/11 (90.9%)         9/11           neurological/congnitive manifestations (n (%))         11/11 (100%)         10/11           Self reported symptoms          10/11 (90.9%)         10/11           Flu-like symptoms (n (%))         10/11 (90.9%)         10/11         10/11           Dyspnoe (n (%))         10/11 (90.9%)         11/11         10/0%)         11/11           Dyspnoe (n (%))         10/11 (90.9%)         11/11         10/14         10/14         11/14         11/14         11/14         11/14         11/14         11/14         11/14         11/14	(7.2) 0	).37 <sup>¥</sup>
Mental health (Mean (SD))         51,7 (14.1)         60,7           Vitality (Mean (SD))         13,9 (13.19         15,5           Role-emotional (Mean (SD))         66,6 (43.1)         81,5           Social functioning (Mean (SD))         13,4 (14)         17 (           General health (Mean (SD))         22 ± (2)         22,7           Bodily pain (Mean (SD))         28,6 (27)         36,2           Other questionaries         Chalder Fatigue Scale (bm) (Mean (SD))         10.3 (0.9)         9,2           Bell Score (Mean (SD))         30 (7.4)         31.8           Canadian criteria for ME/CFS (n (%))         10/11 (90.9%)         9/11           neurological/congnitive manifestations (n (%))         11/11 (100%)         10/1           Self reported symptoms         Flu-like symptoms (n (%))         10/11 (90.9%)         8/11           Tiredness (n (%))         10/11 (90.9%)         8/11         11/1           Dyspnoe (n (%))         11/11 (100%)         11/11         11/14           Odor changes in taste (n (%))         2/11 (18.2%)         1/11           Changes in taste (n (%))         2/11 (18.2%)         1/11           Odor changes (n (%))         2/11 (18.2%)         1/11           Changes in taste (n (%))         2/11 (18.2%) <td< td=""><td>. ,</td><td></td></td<>	. ,	
Vitality (Mean (SD))       13,9 (13.19       15,5         Role-emotional (Mean (SD))       66,6 (43.1)       81,8         Social functioning (Mean (SD))       13,4 (14)       17 (         General health (Mean (SD))       22 ± (2)       22,7         Bodily pain (Mean (SD))       22 ± (2)       22,7         Bodily pain (Mean (SD))       28,6 (27)       36,2         Other questionaries       7       7         Chalder Fatigue Scale (bm) (Mean (SD))       10.3 (0.9)       9,2         Bell Score (Mean (SD))       30 (7.4)       31.8         Canadian criteria for ME/CFS (n (%))       10/11 (90.9%)       9/11         neurological/congnitive manifestations (n (%))       11/11 (100%)       11/17         Self reported symptoms       7       7       7         Flu-like symptoms (n (%))       10/11 (90.9%)       10/11       9.9         Persistent cough (n (%))       10/11 (90.9%)       10/11       11/11         Dyspnoe (n (%))       10/11 (90.9%)       10/11       11/11         Respiratory pain (n (%))       10/11 (90.9%)       11/11       11/11         Odor changes (n (%))       2/11 (18.2%)       1/11       1/11         Odor changes (n (%))       2/11 (18.2%)       1/11       1/	′ (16.7) C	).12 <sup>¥</sup>
Role-emotional (Mean (SD))       66,6 (43.1)       81,8         Social functioning (Mean (SD))       13,4 (14)       17 (         General health (Mean (SD))       22 ± (2)       22,7         Bodily pain (Mean (SD))       22 ± (2)       22,7         Bodily pain (Mean (SD))       28,6 (27)       36,2         Other questionaries	) (12) 1	1.00 <sup>¥</sup>
Social functioning (Mean (SD))         13,4 (14)         17 (           General health (Mean (SD))         22 ± (2)         22,7           Bodily pain (Mean (SD))         28,6 (27)         36,2           Other questionaries	3 (38.6)	) 41 <sup>¥</sup>
General health (Mean (SD))         22 ± (2)         22,7           Bodily pain (Mean (SD))         28,6 (27)         36,2           Other questionaries         28,6 (27)         36,2           Chalder Fatigue Scale (bm) (Mean (SD))         10,3 (0.9)         9.2           Bell Score (Mean (SD))         30 (7.4)         31.5           Canadian criteria for ME/CFS (n (%))         10/11 (90.9%)         9/11           neurological/congnitive manifestations (n (%))         11/11 (100%)         10/11           Self reported symptoms         10/11 (90.9%)         10/11           Flu-like symptoms (n (%))         10/11 (90.9%)         10/11           Dyspnoe (n (%))         10/11 (90.9%)         10/11           Dyspnoe (n (%))         10/11 (90.9%)         10/11           Triedness (n (%))         10/11 (90.9%)         8/11           Tiredness (n (%))         10/11 (90.9%)         11/11           Odor changes (n (%))         2/11 (18.2%)         1/11           Odor changes in taste (n (%))         2/11 (18.2%)         1/11	15 3) C	).31 <sup>¥</sup>
Bodily pain (Mean (SD))         28,6 (27)         36,2           Other questionaries         Chalder Fatigue Scale (bm) (Mean (SD))         10.3 (0.9)         9.2           Bell Score (Mean (SD))         30 (7.4)         31.8           Canadian criteria for ME/CFS (n (%))         10/11 (90.9%)         9/11           neurological/congnitive manifestations (n (%))         11/11 (100%)         10/1           Immunological manifestations (n (%))         11/11 (100%)         10/1           Self reported symptoms         Flu-like symptoms (n (%))         10/11 (90.9%)         8/11           Tiredness (n (%))         10/11 (90.9%)         8/11         11/11 (100%)         11/11           Dyspnoe (n (%))         10/11 (90.9%)         8/11         11/11 (100%)         11/11           Dyspnoe (n (%))         10/11 (90.9%)         8/11         11/11 (100%)         11/11           Dyspnoe (n (%))         10/11 (90.9%)         8/11         11/11         100%)         11/11           Dyspnoe (n (%))         10/11 (90.9%)         11/11         10/10%)         11/11           Dyspnoe (n (%))         2/11 (18.2%)         1/11         11/11         11/11         11/11         11/11         11/11         11/11         11/11         11/11         11/11         11/11 <td>' (12.3)</td> <td>) 72<sup>¥</sup></td>	' (12.3)	) 72 <sup>¥</sup>
Other questionaries         20,0 (21)         30,2           Other questionaries         Chalder Fatigue Scale (bm) (Mean (SD))         10.3 (0.9)         9.2           Bell Score (Mean (SD))         30 (7.4)         31.6           Canadian criteria for ME/CFS (n (%))         10/11 (90.9%)         9/11           neurological/congnitive manifestations (n (%))         11/11 (100%)         10/1           Self reported symptoms         11/11 (100%)         11/1           Self reported symptoms (n (%))         10/11 (90.9%)         10/1           Persistent cough (n (%))         10/11 (90.9%)         10/1           Dyspnoe (n (%))         10/11 (90.9%)         8/11           Tiredness (n (%))         10/11 (90.9%)         8/11           Tiredness (n (%))         11/11 (100%)         11/1           Respiratory pain (n (%))         0/11 (0%)         1/11           Odor changes (n (%))         2/11 (18.2%)         1/11           Odor changes (n (%))         2/11 (18.2%)         1/11           Changes in taste (n (%))         2/11 (18.2%)         1/11           Changes in taste (n (%))         5/11 (45.5%)         6/11           Cephalgien (n (%))         8/11 (72.7%)         7/11           Myalgien (n (%))         8/11 (72.7%)         8	(12.0) 0 (25.5) c	ν.η <u>2</u>
Chalder Fatigue Scale (bm) (Mean (SD))         10.3 (0.9)         9.2           Bell Score (Mean (SD))         30 (7.4)         31.8           Canadian criteria for ME/CFS (n (%))         10/11 (90.9%)         9/11           neurological/congnitive manifestations (n (%))         11/11 (100%)         10/1           Immunological manifestations (n (%))         11/11 (100%)         10/1           Self reported symptoms         10/11 (90.9%)         10/1           Self reported symptoms (n (%))         10/11 (90.9%)         10/1           Persistent cough (n (%))         10/11 (90.9%)         10/1           Dyspnoe (n (%))         10/11 (90.9%)         8/11           Tiredness (n (%))         10/11 (90.9%)         11/1           Respiratory pain (n (%))         0/11 (0%)         11/1           Odor changes (n (%))         2/11 (18.2%)         1/11           Odor changes (n (%))         2/11 (18.2%)         1/11           Changes in taste (n (%))         2/11 (18.2%)         1/11           Changes in taste (n (%))         5/11 (45.5%)         6/11           Cephalgien (n (%))         10/11 (90.9%)         11/1           Myalgien (n (%))         8/11 (72.7%)         7/11           Limb pain (n (%))         8/11 (72.7%)         8/11 </td <td>. (23.3) 0</td> <td>1.09</td>	. (23.3) 0	1.09
Bell Score (Mean (SD))         30 (7.4)         31.6           Canadian criteria for ME/CFS (n (%))         10/11 (90.9%)         9/11           neurological/congnitive manifestations (n (%))         11/11 (100%)         10/1           Immunological manifestations (n (%))         11/11 (100%)         10/1           Self reported symptoms         11/11 (90.9%)         10/11           Self reported symptoms         11/11 (90.9%)         10/11           Persistent cough (n (%))         10/11 (90.9%)         10/11           Dyspnoe (n (%))         10/11 (90.9%)         8/11           Tiredness (n (%))         10/11 (90.9%)         8/11           Tiredness (n (%))         10/11 (90.9%)         11/1           Odor changes (n (%))         11/11 (100%)         11/11           Odor changes (n (%))         2/11 (18.2%)         1/11           Odor changes (n (%))         2/11 (18.2%)         1/11           Changes in taste (n (%))         2/11 (18.2%)         1/11           Cephalgien (n (%))         5/11 (45.5%)         6/11           Cephalgien (n (%))         8/11 (72.7%)         7/11           Myalgien (n (%))         8/11 (72.7%)         8/11           Unusual abdominal pain (n (%))         2/11 (18.2%)         0/11	(2.2)	) 28 <sup>¥</sup>
Canadian criteria for ME/CFS (n (%))       10/11 (90.9%)       9/11         neurological/congnitive manifestations (n (%))       11/11 (100%)       10/1         Immunological manifestations (n (%))       11/11 (100%)       10/1         Self reported symptoms       11/11 (90.9%)       10/1         Self reported symptoms       10/11 (90.9%)       10/1         Self reported symptoms (n (%))       10/11 (90.9%)       10/1         Persistent cough (n (%))       10/11 (90.9%)       8/11         Dyspnoe (n (%))       10/11 (90.9%)       8/11         Tiredness (n (%))       10/11 (90.9%)       8/11         Tiredness (n (%))       0/11 (10%)       11/1         Odor changes (n (%))       2/11 (18.2%)       1/11         Odor changes (n (%))       2/11 (18.2%)       1/11         Changes in taste (n (%))       2/11 (18.2%)       1/11         Rhinorrhoe (n (%))       5/11 (45.5%)       6/11         Cephalgien (n (%))       8/11 (72.7%)       7/11         Myalgien (n (%))       8/11 (72.7%)       8/11         Unusual abdominal pain (n (%))       4/11 (36.4%)       4/11         Nausea (n (%))       2/11 (18.2%)       0/11	() 0 8 (11 1) 0	).20 ).57 <sup>¥</sup>
neurological/congnitive manifestations (n (%))         11/11 (100%)         11/11           Self reported symptoms         11/11 (100%)         11/11           Self reported symptoms         10/11 (90.9%)         10/11           Persistent cough (n (%))         1/11 (90.9%)         10/11           Dyspnoe (n (%))         1/11 (90.9%)         10/11           Dyspnoe (n (%))         10/11 (90.9%)         8/11           Tiredness (n (%))         10/11 (90.9%)         8/11           Tiredness (n (%))         10/11 (90.9%)         8/11           Thoracic Pain (n (%))         0/11 (0%)         11/11           Odor changes (n (%))         2/11 (18.2%)         1/11           Changes in taste (n (%))         2/11 (18.2%)         1/11           Rhinorrhoe (n (%))         5/11 (45.5%)         6/11           Cephalgien (n (%))         8/11 (72.7%)         7/11           Myalgien (n (%))         8/11 (72.7%)         8/11           Unusual abdominal pain (n (%))         4/11 (36.4%)         4/11           Nausea (n (%))         2/11 (18.2%)         0/11	(81.8%) 1	1.00*
Immunological manifestations (n (%))         11/11 (100%)         11/1           Self reported symptoms         Flu-like symptoms (n (%))         10/11 (90.9%)         10/1           Persistent cough (n (%))         1/11 (91.9%)         0/11           Dyspnoe (n (%))         10/11 (90.9%)         8/11           Tiredness (n (%))         10/11 (90.9%)         8/11           Tiredness (n (%))         10/11 (100%)         11/11           Respiratory pain (n (%))         0/11 (0%)         11/11           Odor changes (n (%))         2/11 (18.2%)         1/11           Odor changes (n (%))         2/11 (18.2%)         1/11           Changes in taste (n (%))         2/11 (18.2%)         1/11           Rhinorrhoe (n (%))         5/11 (45.5%)         6/11           Cephalgien (n (%))         10/11 (90.9%)         11/11           Myalgien (n (%))         8/11 (72.7%)         7/11           Limb pain (n (%))         8/11 (72.7%)         8/11           Unusual abdominal pain (n (%))         4/11 (36.4%)         4/11           Nausea (n (%))         2/11 (18.2%)         0/11	1 (90.9%)	.00*
Self reported symptoms           Flu-like symptoms (n (%))         10/11 (90.9%)         10/1           Persistent cough (n (%))         1/11 (9.1%)         0/11           Dyspnoe (n (%))         10/11 (90.9%)         8/11           Tiredness (n (%))         10/11 (90.9%)         8/11           Tiredness (n (%))         10/11 (100%)         11/11           Respiratory pain (n (%))         0/11 (0%)         1/11           Odor changes (n (%))         2/11 (18.2%)         1/11           Odor changes (n (%))         2/11 (18.2%)         1/11           Changes in taste (n (%))         2/11 (18.2%)         1/11           Rhinorrhoe (n (%))         5/11 (45.5%)         6/11           Cephalgien (n (%))         10/11 (90.9%)         11/11           Myalgien (n (%))         8/11 (72.7%)         7/11           Limb pain (n (%))         8/11 (72.7%)         8/11           Unusual abdominal pain (n (%))         4/11 (36.4%)         4/11           Nausea (n (%))         2/11 (18.2%)         0/11	1 (100%) 1	.00*
Flu-like symptoms (n (%))10/11 (90.9%)10/1Persistent cough (n (%))1/11 (9.1%)0/11Dyspnoe (n (%))10/11 (90.9%)8/11Tiredness (n (%))10/11 (90.9%)8/11Respiratory pain (n (%))0/11 (10%)11/11Thoracic Pain (n (%))2/11 (18.2%)1/11Odor changes (n (%))2/11 (18.2%)1/11Changes in taste (n (%))2/11 (18.2%)1/11Rhinorrhoe (n (%))2/11 (18.2%)1/11Myalgien (n (%))10/11 (90.9%)11/11Limb pain (n (%))8/11 (72.7%)7/11Limb pain (n (%))8/11 (72.7%)8/11Nausea (n (%))2/11 (18.2%)0/11		
Persistent cough (n (%))       1/11 (9.1%)       0/11         Dyspnoe (n (%))       10/11 (90.9%)       8/11         Tiredness (n (%))       11/11 (100%)       11/1         Respiratory pain (n (%))       0/11 (0%)       1/11         Thoracic Pain (n (%))       2/11 (18.2%)       1/11         Odor changes (n (%))       2/11 (18.2%)       1/11         Odor changes (n (%))       2/11 (18.2%)       1/11         Changes in taste (n (%))       2/11 (18.2%)       1/11         Rhinorrhoe (n (%))       5/11 (45.5%)       6/11         Cephalgien (n (%))       10/11 (90.9%)       11/1         Myalgien (n (%))       8/11 (72.7%)       7/11         Limb pain (n (%))       8/11 (72.7%)       8/11         Unusual abdominal pain (n (%))       4/11 (36.4%)       4/11         Nausea (n (%))       2/11 (18.2%)       0/11	1 (90.9%) 1	.00*
Dyspnoe (n (%))10/11 (90.9%)8/11Tiredness (n (%))11/11 (100%)11/1Respiratory pain (n (%))0/11 (0%)1/11Thoracic Pain (n (%))2/11 (18.2%)1/11Odor changes (n (%))2/11 (18.2%)1/11Changes in taste (n (%))2/11 (18.2%)1/11Rhinorrhoe (n (%))2/11 (18.2%)1/11Cephalgien (n (%))5/11 (45.5%)6/11Cephalgien (n (%))10/11 (90.9%)11/1Myalgien (n (%))8/11 (72.7%)7/11Limb pain (n (%))8/11 (72.7%)8/11Unusual abdominal pain (n (%))4/11 (36.4%)4/11Nausea (n (%))2/11 (18.2%)0/11	(0%) 1	.00*
Tiredness (n (%))11/11 (100%)11/1Respiratory pain (n (%))0/11 (0%)1/11Thoracic Pain (n (%))2/11 (18.2%)1/11Odor changes (n (%))2/11 (18.2%)1/11Changes in taste (n (%))2/11 (18.2%)1/11Rhinorrhoe (n (%))2/11 (18.2%)1/11Cephalgien (n (%))5/11 (45.5%)6/11Myalgien (n (%))10/11 (90.9%)11/11Limb pain (n (%))8/11 (72.7%)7/11Unusual abdominal pain (n (%))4/11 (36.4%)4/11Nausea (n (%))2/11 (18.2%)0/11	(72.7%) 0	).57*
Respiratory pain (n (%))       0/11 (0%)       1/11         Thoracic Pain (n (%))       2/11 (18.2%)       1/11         Odor changes (n (%))       2/11 (18.2%)       1/11         Changes in taste (n (%))       2/11 (18.2%)       1/11         Rhinorrhoe (n (%))       2/11 (18.2%)       1/11         Rhinorrhoe (n (%))       5/11 (45.5%)       6/11         Cephalgien (n (%))       10/11 (90.9%)       11/1         Myalgien (n (%))       8/11 (72.7%)       7/11         Limb pain (n (%))       8/11 (72.7%)       8/11         Unusual abdominal pain (n (%))       4/11 (36.4%)       4/11         Nausea (n (%))       2/11 (18.2%)       0/11	1 (100%) 1	.00*
Thoracic Pain (n (%))       2/11 (18.2%)       1/11         Odor changes (n (%))       2/11 (18.2%)       1/11         Changes in taste (n (%))       2/11 (18.2%)       1/11         Rhinorrhoe (n (%))       2/11 (18.2%)       1/11         Cephalgien (n (%))       5/11 (45.5%)       6/11         Myalgien (n (%))       10/11 (90.9%)       11/1         Limb pain (n (%))       8/11 (72.7%)       7/11         Unusual abdominal pain (n (%))       4/11 (36.4%)       4/11         Nausea (n (%))       2/11 (18.2%)       0/11	(9.1%) 1	.00*
Odor changes (n (%))       2/11 (18.2%)       1/11         Changes in taste (n (%))       2/11 (18.2%)       1/11         Rhinorrhoe (n (%))       5/11 (45.5%)       6/11         Cephalgien (n (%))       10/11 (90.9%)       11/1         Myalgien (n (%))       8/11 (72.7%)       7/11         Limb pain (n (%))       8/11 (72.7%)       8/11         Unusual abdominal pain (n (%))       4/11 (36.4%)       4/11         Nausea (n (%))       2/11 (18.2%)       0/11	(9.1%) 1	.00*
Changes in taste (n (%))       2/11 (18.2%)       1/11         Rhinorrhoe (n (%))       5/11 (45.5%)       6/11         Cephalgien (n (%))       10/11 (90.9%)       11/1         Myalgien (n (%))       8/11 (72.7%)       7/11         Limb pain (n (%))       8/11 (72.7%)       8/11         Unusual abdominal pain (n (%))       4/11 (36.4%)       4/11         Nausea (n (%))       2/11 (18.2%)       0/11	(9.1%) 1	.00*
Rhinorrhoe (n (%))       5/11 (45.5%)       6/11         Cephalgien (n (%))       10/11 (90.9%)       11/1         Myalgien (n (%))       8/11 (72.7%)       7/11         Limb pain (n (%))       8/11 (72.7%)       8/11         Unusual abdominal pain (n (%))       4/11 (36.4%)       4/11         Nausea (n (%))       2/11 (18.2%)       0/11	(9.1%) 1	.00*
Cephalgien (n (%))       10/11 (90.9%)       11/1         Myalgien (n (%))       8/11 (72.7%)       7/11         Limb pain (n (%))       8/11 (72.7%)       8/11         Unusual abdominal pain (n (%))       4/11 (36.4%)       4/11         Nausea (n (%))       2/11 (18.2%)       0/11	(54.5%) 1	.00*
Myalgien (n (%))       8/11 (72.7%)       7/11         Limb pain (n (%))       8/11 (72.7%)       8/11         Unusual abdominal pain (n (%))       4/11 (36.4%)       4/11         Nausea (n (%))       2/11 (18.2%)       0/11	1 (100%) 1	.00*
Limb pain (n (%)) 8/11 (72.7%) 8/11 Unusual abdominal pain (n (%)) 4/11 (36.4%) 4/11 Nausea (n (%)) 2/11 (18.2%) 0/11	(63.6%) 1	.00*
Unusual abdominal pain (n (%)) 4/11 (36.4%) 4/11 Nausea (n (%)) 2/11 (18.2%) 0/11	(72.7%) 1	.00*
Nausea (n (%)) 2/11 (18.2%) 0/11	(36.4%) 1	.00*
	(0%) 0	).47*
Diarrhoea (n (%)) 3/11 (27.3%) 1/11	(9.1%) 0	).59*
Confusion, disorientation or drowsiness (n (%)) 4/11 (36.4%) 2/11	(18.2%) 0	).64*
Brain Fog (n (%)) 10/11 (90.9%) 11/1	1 (100%) 1	.00*
Sleep disorders (n (%)) 9/11 (81.8%) 9/11	(81.8%) 1	.00*
Lack of drive (n (%)) 3/11 (27.3%) 2/11	(18.2%) 1	.00*

802 U Test

It is made available under a CC-BY-NC-ND 4.0 International license .

804 Figure 1. Influence of IA-Therapy on ANSR -AABs and physiological, 805 neuropsychological and cardiological health. (A) Study protocol and time points for 806 various examinations and blood samples. (B) ELISA analysis of the concentration of  $\beta 1/\beta 2$ -807 adrenoceptors and muscarinic M3/M4 receptors before IA (D0), immediately after the last IA 808 session (D10), and 30 days later (D40). (C) Hand strength measurement before and 30 days 809 after the last IA session. (D) Results of the neuropsychological test battery CERAD-Plus 810 before and 30 days after the last IA session. Pairwise Man-Whitney U Test was performed.

#### 811 Figure 2. Temporary reduction of pro-inflammatory cytokines after IA-Therapy.

- 812 Analysis of the cytokine profile of IA patients before IA, immediately after IA and 30 days
- 813 after the last IA. Pairwise Man-Whitney U Test was performed.

814 Figure 3. Percentage of T cell populations and ANSR-specific T cells. PBMCs from 815 patients were isolated before IA (D0), and 30 days after the last IA (D40) and stained with the 816 appropriate antibodies and analyzed in a flow-cytometer. (A+C) T cells were identified as 817 CD3<sup>+</sup> and CD4<sup>+</sup> or CD8<sup>+</sup>. Naïve and memory T cells were distinguished by expression of 818 CD45RA and CCR7, follicular helper cells by CXCR5 and exhausted T cells by expression of 819 PD-1. CM = Central Memory, EM = Effector Memory. (B+D) PBMC were stimulate for 18h 820 with SARS-CoV-2 Spike OPPs, β1/β2-adrenoreceptors or muscarinic M3/M4 receptor cell 821 lysates, stained with the appropriate antibodies and analyzed in a flow-cytometer. Activated 822 T helper cells were identified as CD4<sup>+</sup> CD154<sup>+</sup>CD137<sup>+</sup> and activated cytotoxic T cells as 823 CD8<sup>+</sup>CD137<sup>+</sup>. Pairwise Man-Whitney U Test was performed. Gating strategies are depicted 824 in supplementary figure S5+S6.

825 Figure 4. Some of the patients have soluble spike protein, which is correlated with 826 ANSR AAB and blood levels of cytokines. (A) Concentration of spike protein in all spike 827 positive patients (6/12). (B) Concentration of serum antibodies against SARS-CoV-2 spike 828 protein. (C) Percentage of spike protein specific T cells. PBMC were stimulated for 18h with 829 a SARS-CoV-2 spike protein overlapping peptide pool. Spike specific T helper cells were 830 identified as CD4<sup>+</sup>CD154<sup>+</sup>CD137<sup>+</sup> and spike specific cytotoxic T cells as CD8<sup>+</sup>CD137<sup>+</sup> 831 among all CD4 or CD8 T cells. (D+E) Correlation matrices of spike+ and spike- patients with 832 ANSR AABs vs. blood cytokines (D) and neurological test (E). All collected values were 833 tested for correlation. P-values are shown as asterisks within the boxes. p < 0.05, p < 0.01, 834 \*\*\*p < 0.001, \*\*\*\*p < 0.0001. Color grading refers to Spearman's rho rank correlation and is 835 indicated as legend underneath the correlation matrix.





Α



0.00049 0.00049 100 -50

D10

D40

DO

Beta2-AR





M4-AR







Word learning











IL-1ß

TNF









IL-17A





0.36

D10

D30

0.1

0.042

20 -

15 -

5 -

0 -

D0

Ju 10 -



















TEMRA CD8+



PD1 CD8+



CD8+CD137+





D

0.6

0.4

0.2



Ε

D30



